Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28246288 | 1.00 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL28229178 | 1.00 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| Bicarbonate SCHEMBL9827045 | 0.97 | GAA (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL29842368 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL791466 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL31580592 | 0.91 | MAPK1 (0.48) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL953293 | 0.91 | GNAI3 (0.55) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL10442815 | 0.91 | KCNH2 (0.44) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL7365544 | 0.90 | EPHX1 (0.49) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL3332407 | 0.87 | NAAA (0.52) | GAAMAPK1HTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0391169-A2 | Enantiomeric pure 7-(3-amino-1-pyrrolidinyl)-chinolon-and-naphthyridon carboxylic acids | BAYER AG (DE) | 1990-10-10 | — | — | EP | claimed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-3102193-B1 | ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES | UNIV RUTGERS (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-113365996-A | Imidazopyridine derivative compounds and uses thereof | 韩美药品株式会社 | 2021-09-07 | — | — | CN | disclosed |
| EP-3710458-A1 | IMMUNOPROTEASOME INHIBITORS | Principia Biopharma Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018165611-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2018134731-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-26 | — | — | WO | disclosed |
| US-9919998-B2 | Antibacterial agents: Nα-aroyl-N-aryl-phenylalaninamides | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3169679-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE4 INHIBITORS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20030166681-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-04 | — | — | US | disclosed |
| US-6538017-B2 | Anticoagulants; cardiovascular disorders; central nervous system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-03-25 | — | — | US | disclosed |
| US-20030004186-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002076945-A1 | AMINOPYRROLIDINE SULFONAMIDES AS SERINE PROTEASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | DAX SCOTT L (US) | 2002-08-22 | — | — | US | disclosed |
| US-6380224-B1 | FOR THERAPY OF EATING DISORDERS, OBESITY, BULIMIA NERVOSA, DIABETES, MEMORY LOSS, EPILEPTIC SEIZURES, MIGRAINE, SLEEP DISTURBANCES, PAIN, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION AND ANXIETY | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-0391169-A2 | Enantiomeric pure 7-(3-amino-1-pyrrolidinyl)-chinolon-and-naphthyridon carboxylic acids | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0200307-B1 | IMPROVED PROCESS FOR PRODUCTION OF QUINOLINE-3-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1989-12-20 | — | — | EP | disclosed |
| EP-0302525-A2 | Quinolones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-02-08 | — | — | EP | disclosed |
| EP-0200307-A1 | Improved process for production of quinoline-3-carboxylic acid antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166681-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | PRSS1, DNPEP, PRSS2 | GAA 864/4885MAPK1 4041/4885HTT 3425/4885 |
| US-20030004186-A1 | Aminopyrrolidine sulfonamides as serine protease inhibitors | PRSS1, DNPEP, PRSS2 | GAA 864/4885MAPK1 4041/4885HTT 3425/4885 |
| US-20020115715-A1 | Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders | NPY5R, NPY1R, NPY2R | GAA 1034/4885MAPK1 1523/4885HTT 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.